Bavencio (avelumab)

About Merck KGaA

Merck KGaA's mission is to advance science and technology to improve lives and solve pressing challenges. Its key achievements include building a leading oncology franchise with Bavencio, establishing MilliporeSigma as a dominant global supplier to the life science industry, and becoming a critical materials partner for the electronics sector. The company's strategy leverages its deep scientific expertise across its three interconnected pillars to capitalize on long-term trends in healthcare digitization, biopharma outsourcing, and technological miniaturization.

About EMD Serono

EMD Serono is a well-established, commercial-stage biopharmaceutical company and a key regional pillar of the global Merck KGaA healthcare group. With a legacy dating back to 1971, it has built a strong commercial presence in high-need therapeutic areas, particularly reproductive health, neurology, and oncology. The company's strategy involves commercializing the global parent's pipeline in North America while also engaging in targeted business development to expand its portfolio. As a subsidiary of a large, diversified multinational, it benefits from significant R&D resources and financial stability while focusing on specialty care markets with significant unmet needs.

Therapeutic Areas